192 related articles for article (PubMed ID: 32132638)
1. Immunotherapeutic potential of CD4 and CD8 single-positive T cells in thymic epithelial tumors.
Yamamoto Y; Iwahori K; Funaki S; Matsumoto M; Hirata M; Yoshida T; Kanzaki R; Kanou T; Ose N; Minami M; Sato E; Kumanogoh A; Shintani Y; Okumura M; Wada H
Sci Rep; 2020 Mar; 10(1):4064. PubMed ID: 32132638
[TBL] [Abstract][Full Text] [Related]
2. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
Arbour KC; Naidoo J; Steele KE; Ni A; Moreira AL; Rekhtman N; Robbins PB; Karakunnel J; Rimner A; Huang J; Riely GJ; Hellmann MD
PLoS One; 2017; 12(8):e0182665. PubMed ID: 28771603
[TBL] [Abstract][Full Text] [Related]
3. Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors.
Tateo V; Manuzzi L; De Giglio A; Parisi C; Lamberti G; Campana D; Pantaleo MA
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260538
[TBL] [Abstract][Full Text] [Related]
4. PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus.
Marchevsky AM; Walts AE
Hum Pathol; 2017 Feb; 60():16-23. PubMed ID: 27746267
[TBL] [Abstract][Full Text] [Related]
5. Thymic epithelial tumors: From biology to treatment.
Conforti F; Pala L; Giaccone G; De Pas T
Cancer Treat Rev; 2020 Jun; 86():102014. PubMed ID: 32272379
[TBL] [Abstract][Full Text] [Related]
6. Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma.
Owen D; Chu B; Lehman AM; Annamalai L; Yearley JH; Shilo K; Otterson GA
J Thorac Oncol; 2018 Aug; 13(8):1204-1212. PubMed ID: 29702286
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives.
Ao YQ; Gao J; Wang S; Jiang JH; Deng J; Wang HK; Xu B; Ding JY
Mol Cancer; 2023 Apr; 22(1):70. PubMed ID: 37055838
[TBL] [Abstract][Full Text] [Related]
8. Diffuse high intensity PD-L1 staining in thymic epithelial tumors.
Padda SK; Riess JW; Schwartz EJ; Tian L; Kohrt HE; Neal JW; West RB; Wakelee HA
J Thorac Oncol; 2015 Mar; 10(3):500-8. PubMed ID: 25402569
[TBL] [Abstract][Full Text] [Related]
9. Impact of PD-L1, transforming growth factor-β expression and tumor-infiltrating CD8
Duan J; Liu X; Chen H; Sun Y; Liu Y; Bai H; Wang J
Thorac Cancer; 2018 Nov; 9(11):1341-1353. PubMed ID: 30168897
[TBL] [Abstract][Full Text] [Related]
10. Unraveling the Immune Microenvironment of Thymic Epithelial Tumors: Implications for Autoimmunity and Treatment.
Masaoutis C; Palamaris K; Kokkali S; Levidou G; Theocharis S
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887212
[TBL] [Abstract][Full Text] [Related]
11. Flow cytometric analysis of lymphoid cells in thymic epithelial neoplasms.
Nakajima J; Takamoto S; Oka T; Tanaka M; Takeuchi E; Murakawa T
Eur J Cardiothorac Surg; 2000 Sep; 18(3):287-92. PubMed ID: 10973537
[TBL] [Abstract][Full Text] [Related]
12. T-cell development in human thymoma.
Inoue M; Fujii Y; Okumura M; Miyoshi S; Shiono H; Fukuhara K; Kadota Y; Matsuda H
Pathol Res Pract; 1999; 195(8):541-7. PubMed ID: 10483584
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the effectiveness of chemotherapy for thymic epithelial tumors using the CD-DST method.
Yu L; Zhang BX; Du X; Yu Z; Yang XG; Jiang YX
Thorac Cancer; 2020 May; 11(5):1160-1169. PubMed ID: 32196982
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis in thymic epithelial tumors.
Park SH; Kim HK; Kim H; Ro JY
Pathol Res Pract; 2002; 198(7):461-7. PubMed ID: 12234065
[TBL] [Abstract][Full Text] [Related]
15. Role of Immunotherapy in Small Cell Lung Cancer, Thymic Epithelial Tumors, and Mesothelioma.
Hann CL; Scherpereel A; Hellyer JA; Wakelee HA
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():543-552. PubMed ID: 31099677
[TBL] [Abstract][Full Text] [Related]
16. The MIC2 antibody 013. Practical application for the study of thymic epithelial tumors.
Chan JK; Tsang WY; Seneviratne S; Pau MY
Am J Surg Pathol; 1995 Oct; 19(10):1115-23. PubMed ID: 7573670
[TBL] [Abstract][Full Text] [Related]
17. Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation.
Bellissimo T; Ganci F; Gallo E; Sacconi A; Tito C; De Angelis L; Pulito C; Masciarelli S; Diso D; Anile M; Petrozza V; Giangaspero F; Pescarmona E; Facciolo F; Venuta F; Marino M; Blandino G; Fazi F
Mol Cancer; 2017 May; 16(1):88. PubMed ID: 28486946
[TBL] [Abstract][Full Text] [Related]
18. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
Tiseo M; Damato A; Longo L; Barbieri F; Bertolini F; Stefani A; Migaldi M; Gnetti L; Camisa R; Bordi P; Buti S; Rossi G
Lung Cancer; 2017 Feb; 104():24-30. PubMed ID: 28212996
[TBL] [Abstract][Full Text] [Related]
19. Arginase Pathway Markers of Immune-Microenvironment in Thymic Epithelial Tumors and Small Cell Lung Cancer.
Umemura S; Chen V; Chahine JJ; Kallakury B; Zhao X; Lee H; Avantaggiati ML; He Y; Wang C; Giaccone G
Clin Lung Cancer; 2022 Mar; 23(2):e140-e147. PubMed ID: 34393062
[TBL] [Abstract][Full Text] [Related]
20. Autoimmunity in thymic epithelial tumors: a not yet clarified pathologic paradigm associated with several unmet clinical needs.
Perrino M; Voulaz E; Balin S; Cazzato G; Fontana E; Franzese S; Defendi M; De Vincenzo F; Cordua N; Tamma R; Borea F; Aliprandi M; Airoldi M; Cecchi LG; Fazio R; Alloisio M; Marulli G; Santoro A; Di Tommaso L; Ingravallo G; Russo L; Da Rin G; Villa A; Della Bella S; Zucali PA; Mavilio D
Front Immunol; 2024; 15():1288045. PubMed ID: 38629065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
